A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer

Table 3 Most common AEs occurring during the study

	Patients experiencing an AE,^a n(%)
	Fulvestrant 500 mg	Fulvestrant 500 mg + anastrozole 1 mg	Anastrozole 1 mg
Hot flash	7 (18)	3 (8)	8 (20)
Headache	3 (8)	4 (10)	3 (8)
Pain in extremity	0 (0)	4 (10)	2 (5)
Constipation	3 (8)	1 (3)	2 (5)
Injection-site pain	2 (5)	1 (3)	3 (8)
Any AE	27 (68)	27 (68)	29 (73)

^aData for the intent-to-treat population. One patient who received no treatment was excluded. AE, adverse event.

ISSN: 1465-542X